Dysthyroidism in dermato/polymyositis patients: A case-control study.
big data
dermatomyositis
hyperthyroidism
hypothyroidism
polymyositis
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
22
11
2020
received:
14
10
2020
accepted:
22
11
2020
pubmed:
8
12
2020
medline:
15
12
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
Dermatomyositis (DM) and polymyositis (PM) are two rare autoimmune disorders occasionally described with dysthyroidism; however, no solid evidence still proves such an association. To evaluate the prevalence of dysthyroidism among DM/PM patients. A nation-wide case-control study was conducted. From the Clalit Health Services health records database, we extracted 2085 (DM = 1475 (70.7%), PM = 610 (29.3%)) PM/DM cases and 10 193 sex-age matched controls in the period 2000-2018. Both univariate and multivariate analyses were performed to evaluate the link dysthyroidism and PM/DM. Survival analysis was also performed. The rate of hyperthyroidism was significantly (P = .0097) higher in cases (n = 40, 1.9%) with respect to controls (n = 123, 1.2%). Similarly, the rate of hypothyroidism was significantly (P < .0001) associated with cases (n = 234, 11.2%) when compared to controls (n = 853, 8.4%). At the multivariate logistic regression analysis, both DM (OR 1.31 [95%CI 1.07-1.60], P = .0087) and PM (OR 1.54 [95%CI 1.21-1.95], P = .004) were significantly associated with hypothyroidism, whereas DM (OR 1.70 [95%CI 1.10-2.61], P = .0165) but not PM (OR 1.45 [0.83-2.55], P = .1947) was found to be associated with hyperthyroidism. Subjects with PM and positive for anti-Sjögren's syndrome-related antigen A (SSA) auto-antibody displayed a significant risk of developing hyperthyroidism (OR 5.85 [95%CI 1.02-33.74], P = .0480), whereas individuals with DM and positive for antinuclear antibody (ANA) had a higher risk of developing hyperthyroidism (OR 2.65 [95%CI 1.00-7.03], P = .0498). Physicians treating PM/DM patients should consider screening for thyroid dysfunction on a regular basis.
Sections du résumé
BACKGROUND
BACKGROUND
Dermatomyositis (DM) and polymyositis (PM) are two rare autoimmune disorders occasionally described with dysthyroidism; however, no solid evidence still proves such an association.
AIM
OBJECTIVE
To evaluate the prevalence of dysthyroidism among DM/PM patients.
DESIGN AND SETTING
METHODS
A nation-wide case-control study was conducted.
METHODS
METHODS
From the Clalit Health Services health records database, we extracted 2085 (DM = 1475 (70.7%), PM = 610 (29.3%)) PM/DM cases and 10 193 sex-age matched controls in the period 2000-2018. Both univariate and multivariate analyses were performed to evaluate the link dysthyroidism and PM/DM. Survival analysis was also performed.
RESULTS
RESULTS
The rate of hyperthyroidism was significantly (P = .0097) higher in cases (n = 40, 1.9%) with respect to controls (n = 123, 1.2%). Similarly, the rate of hypothyroidism was significantly (P < .0001) associated with cases (n = 234, 11.2%) when compared to controls (n = 853, 8.4%). At the multivariate logistic regression analysis, both DM (OR 1.31 [95%CI 1.07-1.60], P = .0087) and PM (OR 1.54 [95%CI 1.21-1.95], P = .004) were significantly associated with hypothyroidism, whereas DM (OR 1.70 [95%CI 1.10-2.61], P = .0165) but not PM (OR 1.45 [0.83-2.55], P = .1947) was found to be associated with hyperthyroidism. Subjects with PM and positive for anti-Sjögren's syndrome-related antigen A (SSA) auto-antibody displayed a significant risk of developing hyperthyroidism (OR 5.85 [95%CI 1.02-33.74], P = .0480), whereas individuals with DM and positive for antinuclear antibody (ANA) had a higher risk of developing hyperthyroidism (OR 2.65 [95%CI 1.00-7.03], P = .0498).
CONCLUSIONS
CONCLUSIONS
Physicians treating PM/DM patients should consider screening for thyroid dysfunction on a regular basis.
Substances chimiques
Antibodies, Antinuclear
0
SS-A antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13460Informations de copyright
© 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Mammen A. Autoimmune muscle disease. Handb Clin Neurol. 2016;133:467-484.
Dalakas MC. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006;2(4):219-227.
Ramos-E-Silva M, Pinto AP, Pirmez R, Cuzzi T, Carneiro SC Dermatomyositis-Part 1: Definition, epidemiology, etiology and pathogenesis, and clinics. Skinmed. 2016;14(4):273-279.
Mainetti C, Terziroli Beretta-Piccoli B, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):337-356.
Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10(3):346-352.
Watad A, Cohen AD, Comaneshter D, Tekes-Manova D, Amital H. Hyperthyroidism association with SLE, lessons from real-life data-a case-control study. Autoimmunity. 2016;49(1):17-20.
Mahagna H, Caplan A, Watad A, et al. Rheumatoid arthritis and thyroid dysfunction: A cross-sectional study and a review of the literature. Best Pract Res Clin Rheumatol. 2018;32(5):683-691.
Watad A, Bragazzi NL, Brigo F, et al. Epilepsy is not statistically associated with systemic sclerosis but significantly impacts on mortality: a real-world epidemiological survey-based study. Best Pract Res Clin Rheumatol. 2018;32(5):710-717.
Watad A, McGonagle D, Bragazzi NL, et al. Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival. Oncoimmunology. 2019;8(6):e1588084.
Watad A, Bragazzi NL, McGonagle D, et al. Systemic sclerosis is linked to psoriasis and may impact on patients' survival: a large cohort study. J Clin Med. 2019;8(4):521.
Bragazzi NL, Watad A, Gizunterman A, et al. The burden of depression in systemic sclerosis patients: a nationwide population-based study. J Affect Disord. 2019;243:427-431.
Watad A, Bragazzi NL, Tiosano S, et al. Alzheimer's disease in systemic sclerosis patients: a Nationwide Population-Based Cohort Study. J Alzheimers Dis. 2018;65(1):117-124.
Watad A, Tiosano S, Bragazzi N, et al. Epilepsy among systemic lupus erythematosus patients: insights from a large database analysis. Neuroepidemiology. 2018;50(1-2):1-6.
Nagy E, Szodoray L, Pongracz E. Simultaneous presence of Hashimoto's goiter, dermatomyositis and scleromyxedema. Z Haut Geschlechtskr. 1962;33:26-29.
Gamsky TE, Chan MK. Coexistent dermatomyositis and autoimmune thyroiditis. West J Med. 1988;148(2):213-214.
Go T, Mitsuyoshi I. Juvenile dermatomyositis associated with subclinical hypothyroidism due to auto-immune thyroiditis. Eur J Pediatr. 2002;161(6):358-359.
Charalabopoulos K, Mittari E, Peschos D, et al. Rare association of chronic lymphocytic thyroiditis with dermatomyositis. Arch Med Res. 2006;37(4):563-565.
Lukjanowicz M, Bobrowska-Snarska D, Brzosko M. Coexistence of hypothyroidism with polymyositis or dermatomyositis. Ann Acad Med Stetin. 2006;52(Suppl 2):49-55.
Wang H, Tao L, Li H, Deng J. Dermatomyositis related to autoimmune thyroiditis. J Eur Acad Dermatol Venereol. 2011;25(9):1085-1093.
Ralli M, Angeletti D, Fiore M, et al. Hashimoto's thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev. 2020;19(10):102649.
Perricone C, Agmon-Levin N, Shoenfeld Y. Novel pebbles in the mosaic of autoimmunity. BMC Med. 2013;11(4):101.
Rooyackers OE, Nair KS. Hormonal regulation of human muscle protein metabolism. Annu Rev Nutr. 1997;17:457-485.
Bloise FF, Cordeiro A, Ortiga-Carvalho TM. Role of thyroid hormone in skeletal muscle physiology. J Endocrinol. 2018;236(1):R57-R68.
Zybek-Kocik A, Sawicka-Gutaj N, Szczepanek-Parulska E, et al. The association between irisin and muscle metabolism in different thyroid disorders. Clin Endocrinol (Oxf). 2018;88(3):460-467.
Simonides WS, Thelen MH, van der Linden CG, et al. Mechanism of thyroid-hormone regulated expression of the SERCA genes in skeletal muscle: implications for thermogenesis. Biosci Rep. 2001;21(2):139-154.
Kiss E, Jakab G, Kranias EG, et al. Thyroid hormone-induced alterations in phospholamban protein expression. Regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. Circ Res. 1994;75(2):245-251.
Fisher DJ, Phillips S, McQuinn T. Regulation of SERCA 2 expression by thyroid hormone in cultured chick embryo cardiomyocytes. Am J Physiol. 1996;270(2 Pt 2):H638-H644.
Ketzer LA, Arruda AP, Carvalho DP, et al. Cardiac sarcoplasmic reticulum Ca2+-ATPase: heat production and phospholamban alterations promoted by cold exposure and thyroid hormone. Am J Physiol Heart Circ Physiol. 2009;297(2):H556-H563.
Qiu CC, Su QS, Zhu SY, et al. Identification of potential biomarkers and biological pathways in juvenile dermatomyositis based on miRNA-mRNA network. Biomed Res Int. 2019;2019(7):7814287.
Hayashi A, Takano K, Kawakami Y, et al. Short-term change in resting energy expenditure and body compositions in therapeutic process for Graves' disease. Intern Med. 2020;59(15):1827-1833.
Shahid MA, Ashraf MA, Sharma S. Physiology, Thyroid Hormone. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2020.